Anna Reig1, Pilar Sesé1, Albert Parés1. 1. Liver Unit, Hospital Clínic, IDIBAPS, CIBERehd, University of Barcelona, Barcelona, Spain.
Abstract
OBJECTIVES: Adding fibrates improves liver biochemistries in patients with primary biliary cholangitis (PBC) and suboptimal response to ursodeoxycholic acid (UDCA). As there are no consistent data regarding the course and outcome, we have assessed the effects of the combined treatment with UDCA and bezafibrate on a long-term basis. METHODS: A total of 48 patients (45 female) with PBC treated with UDCA and alkaline phosphatase (ALP) above 1.5 times upper normal levels (× UNL) were treated with bezafibrate (400 mg/day) plus UDCA (13-16 mg/kg/day). Changes in clinical features, liver biochemistries, and prognosis after therapy were assessed, as well as pruritus, using a visual analog scale (43 patients) and the 5-D descriptive pruritus scale. RESULTS: After a median of 38 months, 26 patients (54%) had normalized ALP. In these patients, jaundice, pruritus, and liver stiffness was lower, and age was higher than in patients who remained with elevated ALP. Biochemical improvement was less prominent in patients without ALP normalization. Five of these patients (23%) developed events of disease progression: 1 died, 3 were transplanted, and 1 developed hepatocellular carcinoma. Partial or complete itching relief was reported in all but one case with pruritus. Itching recurrence or worsening was observed after bezafibrate discontinuation. CONCLUSIONS: The long-term treatment with UDCA and bezafibrate results in excellent response, and is associated with a complete or partial itching relief. Incomplete ALP normalization was observed in patients with advanced disease who remained at risk for developing severe events. The combined treatment is mainly effective in patients with lower fibrosis and severity of cholestasis.
OBJECTIVES: Adding fibrates improves liver biochemistries in patients with primary biliary cholangitis (PBC) and suboptimal response to ursodeoxycholic acid (UDCA). As there are no consistent data regarding the course and outcome, we have assessed the effects of the combined treatment with UDCA and bezafibrate on a long-term basis. METHODS: A total of 48 patients (45 female) with PBC treated with UDCA and alkaline phosphatase (ALP) above 1.5 times upper normal levels (× UNL) were treated with bezafibrate (400 mg/day) plus UDCA (13-16 mg/kg/day). Changes in clinical features, liver biochemistries, and prognosis after therapy were assessed, as well as pruritus, using a visual analog scale (43 patients) and the 5-D descriptive pruritus scale. RESULTS: After a median of 38 months, 26 patients (54%) had normalized ALP. In these patients, jaundice, pruritus, and liver stiffness was lower, and age was higher than in patients who remained with elevated ALP. Biochemical improvement was less prominent in patients without ALP normalization. Five of these patients (23%) developed events of disease progression: 1 died, 3 were transplanted, and 1 developed hepatocellular carcinoma. Partial or complete itching relief was reported in all but one case with pruritus. Itching recurrence or worsening was observed after bezafibrate discontinuation. CONCLUSIONS: The long-term treatment with UDCA and bezafibrate results in excellent response, and is associated with a complete or partial itching relief. Incomplete ALP normalization was observed in patients with advanced disease who remained at risk for developing severe events. The combined treatment is mainly effective in patients with lower fibrosis and severity of cholestasis.
Authors: Núria Roglans; Manuel Vázquez-Carrera; Marta Alegret; Ferran Novell; Daniel Zambón; Emilio Ros; Juan C Laguna; Rosa M Sánchez Journal: Eur J Clin Pharmacol Date: 2003-12-18 Impact factor: 2.953
Authors: Palak J Trivedi; Tony Bruns; Angela Cheung; Ka-Kit Li; Clemens Kittler; Teru Kumagi; Husnain Shah; Christopher Corbett; Nadya Al-Harthy; Unsal Acarsu; Catalina Coltescu; Dhiraj Tripathi; Andreas Stallmach; James Neuberger; Harry L A Janssen; Gideon M Hirschfield Journal: J Hepatol Date: 2014-02-15 Impact factor: 25.083
Authors: Frederik Nevens; Pietro Andreone; Giuseppe Mazzella; Simone I Strasser; Christopher Bowlus; Pietro Invernizzi; Joost P H Drenth; Paul J Pockros; Jaroslaw Regula; Ulrich Beuers; Michael Trauner; David E Jones; Annarosa Floreani; Simon Hohenester; Velimir Luketic; Mitchell Shiffman; Karel J van Erpecum; Victor Vargas; Catherine Vincent; Gideon M Hirschfield; Hemant Shah; Bettina Hansen; Keith D Lindor; Hanns-Ulrich Marschall; Kris V Kowdley; Roya Hooshmand-Rad; Tonya Marmon; Shawn Sheeron; Richard Pencek; Leigh MacConell; Mark Pruzanski; David Shapiro Journal: N Engl J Med Date: 2016-08-18 Impact factor: 91.245
Authors: Alena Laschtowitz; Rozanne C de Veer; Adriaan J Van der Meer; Christoph Schramm Journal: United European Gastroenterol J Date: 2020-04-16 Impact factor: 4.623
Authors: Faouzi Saliba; Rafael Bañares; Fin Stolze Larsen; Alexander Wilmer; Albert Parés; Steffen Mitzner; Jan Stange; Valentin Fuhrmann; Stefan Gilg; Tarek Hassanein; Didier Samuel; Josep Torner; Samir Jaber Journal: Intensive Care Med Date: 2022-09-06 Impact factor: 41.787